Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity
Kaoru Saegusa, … , Nobuhiko Katunuma, Yoshio Hayashi
Kaoru Saegusa, … , Nobuhiko Katunuma, Yoshio Hayashi
Published August 1, 2002
Citation Information: J Clin Invest. 2002;110(3):361-369. https://doi.org/10.1172/JCI14682.
View: Text | PDF
Article Immunology

Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity

  • Text
  • PDF
Abstract

Research Article

Authors

Kaoru Saegusa, Naozumi Ishimaru, Kumiko Yanagi, Rieko Arakaki, Kouichi Ogawa, Ichiro Saito, Nobuhiko Katunuma, Yoshio Hayashi

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
(a) Effects of in vivo administration of intraperitoneal injection of ca...
(a) Effects of in vivo administration of intraperitoneal injection of cathepsin inhibitors (Clik60, Clik148, and CA074). Each inhibitor was administered into SS model mice (n = 10 for each) at doses of 0.1 mg/mouse/day from 4 weeks to 7 weeks, and the results were analyzed at 8 weeks compared with those in untreated SS model mice (n = 7). Treatment with intraperitoneal injection of Clik60, but not treatment with Clik 148 and CA074, was effective in preventing the development of autoimmune lesions in the lacrimal, parotid, and submandibular glands of the SS model mice (*P < 0.01, **P < 0.005, Student’s t test). (b) Representative histologic features in the salivary and lacrimal glands showing preventive effects in Clik60-treated mice at 8 weeks of age. (c) The average saliva and tear volume of the SS model mice treated with Clik60 was significantly higher than that of control mice. Results are expressed as mean ± SEM in five mice examined per group (*P < 0.05, **P < 0.005, Student’s t test).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts